Stock Events

Stock Events

Century Therapeutics 

$2.29
11
+$0.03+1.11% Today

Statistics

Day High
2.42
Day Low
2.28
52W High
3.04
52W Low
0.34
Volume
585,875
Avg. Volume
1,864,532
Mkt Cap
197.72M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

20MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.45
-0
0.44
0.89
Expected EPS
-0.1425
Actual EPS
N/A

Financials

-1,920.87%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
13.18MRevenue
-253.13MNet Income

Analyst Ratings

$3.00Average Price Target
The highest estimate is 4.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IPSC. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is a leading company in the gene editing space, directly competing with Century Therapeutics in developing gene-edited cell therapies for various diseases.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine operates in the genome editing field, making it a direct competitor to Century Therapeutics in the development of gene-edited therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology space, competing with Century Therapeutics in creating precise gene editing therapies.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene editing, competing with Century Therapeutics in the development of gene-modified cell therapies.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics is focused on allogeneic CAR T cell therapies, competing with Century Therapeutics in the field of cell therapy for cancer.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies, making it a competitor in the cell therapy space alongside Century Therapeutics.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy arena, particularly in CAR T cell therapies, posing competition to Century Therapeutics.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical focuses on gene therapy for genetic diseases, competing with Century Therapeutics in the broader gene therapy market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer, with its investments in gene therapy and cell therapy, including partnerships and acquisitions, competes in the same therapeutic areas as Century Therapeutics.

About

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Show more...
CEO
Dr. Brent Pfeiffenberger M.B.A., Pharm.D.
Employees
140
Country
US
ISIN
US15673T1007

Listings

XNAS
US
IPSC
BOATS
BOATS
IPSC.BOATS

0 Comments

Share your thoughts

FAQ

What is Century Therapeutics stock price today?▼
The current price of IPSC is $2.29 USD — it has increased by +1.11% in the past 24 hours. Watch Century Therapeutics stock price performance more closely on the chart.
What is Century Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Century Therapeutics stocks are traded under the ticker IPSC.
Is Century Therapeutics stock price growing?▼
IPSC stock has risen by +10.39% compared to the previous week, the month change is a -1.51% fall, over the last year Century Therapeutics has showed a +405.75% increase.
What is Century Therapeutics market cap?▼
Today Century Therapeutics has the market capitalization of 197.72M
When is the next Century Therapeutics earnings date?▼
Century Therapeutics is going to release the next earnings report on May 20, 2026.
What were Century Therapeutics earnings last quarter?▼
IPSC earnings for the last quarter are -0.25 USD per share, whereas the estimation was -0.29 USD resulting in a +13.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Century Therapeutics revenue for the last year?▼
Century Therapeutics revenue for the last year amounts to 13.18M USD.
What is Century Therapeutics net income for the last year?▼
IPSC net income for the last year is -253.13M USD.
How many employees does Century Therapeutics have?▼
As of April 01, 2026, the company has 140 employees.
In which sector is Century Therapeutics located?▼
Century Therapeutics operates in the Health Care sector.
When did Century Therapeutics complete a stock split?▼
Century Therapeutics has not had any recent stock splits.
Where is Century Therapeutics headquartered?▼
Century Therapeutics is headquartered in Philadelphia, US.